259 related articles for article (PubMed ID: 34675109)
1. The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation.
Miyahira AK; Soule HR
J Nucl Med; 2022 Mar; 63(3):331-338. PubMed ID: 34675109
[TBL] [Abstract][Full Text] [Related]
2. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
Plichta KA; Graves SA; Buatti JM
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
[TBL] [Abstract][Full Text] [Related]
3. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
4. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
5. Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
Emmett L
Semin Oncol Nurs; 2020 Aug; 36(4):151052. PubMed ID: 32674976
[TBL] [Abstract][Full Text] [Related]
6. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
9. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer.
Maurer T; Schwamborn K; Schottelius M; Wester HJ; Schwaiger M; Gschwend JE; Eiber M
Clin Genitourin Cancer; 2016 Oct; 14(5):e549-e552. PubMed ID: 27318956
[No Abstract] [Full Text] [Related]
10. PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.
Debnath S; Zhou N; McLaughlin M; Rice S; Pillai AK; Hao G; Sun X
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163083
[TBL] [Abstract][Full Text] [Related]
11. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
Miyahira AK; Pienta KJ; Babich JW; Bander NH; Calais J; Choyke P; Hofman MS; Larson SM; Lin FI; Morris MJ; Pomper MG; Sandhu S; Scher HI; Tagawa ST; Williams S; Soule HR
Prostate; 2020 Nov; 80(15):1273-1296. PubMed ID: 32865839
[TBL] [Abstract][Full Text] [Related]
12. PSMA ligands in prostate cancer - Probe optimization and theranostic applications.
Lütje S; Slavik R; Fendler W; Herrmann K; Eiber M
Methods; 2017 Nov; 130():42-50. PubMed ID: 28666778
[TBL] [Abstract][Full Text] [Related]
13. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Theranostics: PSMA Targeted Therapy.
Seifert R; Alberts IL; Afshar-Oromieh A; Rahbar K
PET Clin; 2021 Jul; 16(3):391-396. PubMed ID: 34053583
[TBL] [Abstract][Full Text] [Related]
15. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?
Sallam M; Nguyen NT; Sainsbury F; Kimizuka N; Muyldermans S; Benešová-Schäfer M
Theranostics; 2024; 14(8):3043-3079. PubMed ID: 38855174
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific membrane antigen as a target for cancer imaging and therapy.
Kiess AP; Banerjee SR; Mease RC; Rowe SP; Rao A; Foss CA; Chen Y; Yang X; Cho SY; Nimmagadda S; Pomper MG
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):241-68. PubMed ID: 26213140
[TBL] [Abstract][Full Text] [Related]
17. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
18.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
19. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.
Iravani A; Violet J; Azad A; Hofman MS
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):38-52. PubMed ID: 31595044
[TBL] [Abstract][Full Text] [Related]
20. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
Kulkarni HR; Singh A; Langbein T; Schuchardt C; Mueller D; Zhang J; Lehmann C; Baum RP
Br J Radiol; 2018 Nov; 91(1091):20180308. PubMed ID: 29762048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]